OnKure says plaintiffs have not pursued two New York suits over its Reneo merger proxy

OnKure Therapeutics, Inc. (Nasdaq: OKUR) still lists two New York lawsuits over its October 2024 merger with Reneo Pharmaceuticals, Inc. as pending, though its 10-Q filed August 4, 2026 says the plaintiffs have not pursued them. The cases are Thomas v. Reneo Pharmaceuticals, Inc., et al., Index No. 654628/2024, filed September 5, 2024, and Kent v. Reneo Pharmaceuticals, Inc., et al., Index No. 654642/2024, filed September 6, 2024. Both are in the Supreme Court of the State of New York, County of New York.

The defendants are Reneo, which became OnKure on completion of the merger, and unnamed individual defendants. The 10-Q says "there has been no activity on either docket."

The case

The complaints generally allege that the proxy statement/prospectus Reneo filed with the SEC misrepresented or omitted material information. They point to Reneo management's financial projections for Reneo and OnKure, the data and inputs behind the valuation analyses supporting the fairness opinion from Leerink Partners, Reneo's financial advisor, and potential conflicts of interest involving Leerink Partners LLC, Evercore Group L.L.C. and LifeSci Capital LLC. Those three firms were placement agents for the concurrent financing that closed with the merger.

The claims are negligent misrepresentation and concealment, and negligence, under New York common law. The plaintiffs asked the court to enjoin the merger or, if it closed, to rescind it or award actual and punitive damages, along with their fees and expenses. These are allegations, and Reneo denied them in September 2024.

Defendants

The 10-Q names only Reneo in the captions and refers to "the individual defendants" without listing them. The proxy statement/prospectus Reneo filed on August 26, 2024, the nearest to the filing dates, lists its directors as Roshawn A. Blunt, Eric M. Dube, Paul W. Hoelscher, Edward T. Mathers, Bali Muralidhar, Niall O'Donnell, Stacey D. Seltzer and Gregory J. Flesher, who was president and chief executive officer. It also lists Michael Grey as executive chairman of the board. Nothing reviewed says these people were sued. Leerink Partners, Evercore and LifeSci Capital are described as advisers and placement agents, not as defendants.

Where it stands

Reneo said in an 8-K filed September 20, 2024 that the complaints had been filed and that it could not predict the outcome of any litigation. It said it believed the proxy disclosures complied fully with applicable law and denied the allegations, but voluntarily supplemented certain disclosures. The company said the supplemental disclosures were not an admission that the complaints had merit.

The merger closed on October 4, 2024, according to the 10-Q. The 10-Q says the plaintiffs "have not pursued their claims," that neither docket shows activity, and that the complaints remain pending. It also says the company and the individual defendants intend to defend against the complaints and similar actions. The 10-Q gives no loss estimate and says OnKure cannot predict the outcome of the complaints or of any other litigation that might be filed over the merger or the concurrent financing.

The 10-Q adds that more lawsuits are possible. Unless they contain new or significantly different allegations, OnKure says it will not necessarily disclose them.

Why it matters to shareholders

The 10-Q reports no accrual for the complaints. It says OnKure has indemnification agreements with its officers and board members that require it to indemnify them against certain liabilities arising from their service. The maximum potential amount of future payments under those agreements is, in many cases, unlimited, according to the filing. The company says it has not incurred any material costs because of such indemnifications and is not aware of any claims under them.

The 10-Q does not say whether insurance would cover any defense costs.

Report an error

Companies in this story

OKUROnKure Therapeutics, Inc.NASDAQ · United StatesOpen the starter desk